OpenAI Launches GPT-Rosalind AI Model for Life Sciences Research and Drug Discovery
OpenAI has launched a new AI model called GPT-Rosalind, named after the famous scientist Rosalind Franklin. This model aims to boost research in fields like biology, drug discovery, and translational medicine by making processes in chemistry, protein engineering, and genomics more efficient. The ultimate goal is to reduce the lengthy drug approval timeline in the U.S., which usually takes 10 to 15 years. Right now, researchers can access it through ChatGPT, Codex, and an API for U.S. Enterprise clients, featuring a plugin that works with over 50 scientific tools. Collaborations with companies such as Amgen and Moderna are underway. Early evaluations show GPT-Rosalind outperforms GPT-5.4 in RNA sequence prediction, ranking in the top 5% of human experts.
Key facts
- GPT-Rosalind is a frontier reasoning model built for life sciences research.
- The model is named after Rosalind Franklin, who helped reveal DNA's structure.
- It is available as a research preview in ChatGPT, Codex, and the API for qualified customers.
- A Life Sciences research plugin for Codex provides access to over 50 scientific tools and data sources.
- OpenAI is working with customers like Amgen, Moderna, and the Allen Institute.
- The model outperforms GPT-5.4 on 6 out of 11 tasks on LABBench2.
- GPT-Rosalind ranked above the 95th percentile of human experts on an RNA sequence prediction task.
- Access is controlled through a trusted-access deployment with enterprise-grade security for U.S. customers.
Entities
Artists
- Rosalind Franklin
Institutions
- OpenAI
- Amgen
- Moderna
- Allen Institute
- Thermo Fisher Scientific
- Dyno Therapeutics
- McKinsey & Company
- Boston Consulting Group
- Bain & Company
- Los Alamos National Laboratory
Locations
- United States